Related Experiment Video
Updated: Jun 13, 2026
15:23
Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease
Published on: May 13, 2010
Simple choline esters as potential anti-Alzheimer agents
Stefano Alcaro1, Rosaria Arcone, Giosuè Costa
1Dipartimento di Scienze Farmacobiologiche Università Magna Graecia di Catanzaro, Campus Universitario, Viale Europa, Catanzaro, Italy. alcaro@unicz.it
Current Pharmaceutical Design
|April 15, 2010
Summary
Researchers developed novel choline esters for Alzheimer's disease treatment, identifying a promising compound with central nervous system cholinergic effects similar to pivaloylcholine.
Area of Science:
- Neuroscience
- Medicinal Chemistry
Background:
- Alzheimer's disease poses a significant challenge, necessitating novel therapeutic agents.
- Pivaloylcholine has demonstrated cholinergic effects in the central nervous system.
- Exploring choline ester analogues is crucial for developing new treatments.
Purpose of the Study:
- To develop simple choline esters as potential therapeutic agents for Alzheimer's disease.
- To identify choline ester analogues with enhanced selectivity for acetylcholinesterase over butyrrylcholinesterase.
- To evaluate the in vivo efficacy of selected choline ester candidates.
Main Methods:
- Utilized crystallographic models of acetylcholine-hydrolyzing enzymes to assess steric compatibility of choline derivatives.
- Conducted enzymatic tests using acetylcholinesterase and butyrrylcholinesterase with two distinct methods.
- Performed in vivo experiments on pre-treated rats, recording electroencephalographic profiles after intraperitoneal administration of candidate compounds.
Main Results:
- Screened and selected two promising choline ester candidates for in vivo testing.
- One selected ester demonstrated biological effects comparable to the parent compound, pivaloylcholine.
- Electroencephalographic profiles confirmed the central nervous system activity of the lead compound.
Conclusions:
- Identified a novel choline ester with potential therapeutic benefits for Alzheimer's disease.
- The developed compound exhibits favorable cholinergic activity and selectivity.
- Further in vivo studies are warranted to confirm the therapeutic potential of this new agent.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:31Direct-Acting Cholinergic Agonists: Pharmacokinetics
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...